Synchronous Bilateral Breast Cancer: Clinical Features, Pathology and Survival Outcomes from a Tertiary Cancer Center

2017 ◽  
Vol 15 (2) ◽  
Author(s):  
Priya Iyer ◽  
Venkatraman Radhakrishnan ◽  
Balasubramanian Ananthi ◽  
Ganesarajah Selvaluxmy ◽  
V Sridevi
2018 ◽  
Vol 39 (1) ◽  
pp. 58
Author(s):  
Abhishek Anand ◽  
LinuAbraham Jacob ◽  
KuntegowdanahalliC Lakshmaiah ◽  
GovindK Babu ◽  
Dasappa Lokanatha ◽  
...  

2014 ◽  
Vol 7 (3) ◽  
pp. 157-161
Author(s):  
K. C. Lakshmaiah ◽  
Umesh Das ◽  
K. Govind Babu ◽  
T. M. Suresh ◽  
D. Lokanatha ◽  
...  

2021 ◽  
Author(s):  
Lingyu Li ◽  
Jiaxuan Li ◽  
Jiwei Jia ◽  
Hua He ◽  
Mingyang Li ◽  
...  

Abstract Background:How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical practice.Methods:Data from Surveillance, Epidemiology, and End Results (SEER) database and the first hospital of Jilin university were analyzed for breast cancer-specific cumulative mortality (BCCM) by competing risk model. Whole-exome sequencing was applied for 10 lesions acquired at spatial-temporal distinct regions from 5 patients to reconstruct clonal evolutionary characteristics of MBBC. Dimensional reduction (DR) cumulative incidence function (CIF) curves of MBBC features were established on different point in diagnostic interval time, to build a novel DR nomogram.Results:Significant heterogeneity in genome and clinical features of MBBC was widespread. The mutational diversity of contralateral BC (CBC) was significantly higher than that in primary BC (PBC), and the most effective prognostic MATH ratio was significantly correlated with interval time (R2=0.85, p < .05). In SEER cohort study (n=13304), the interval time was not only significantly affected the BCCM by multivariate analysis (p < .000), but determined the weight of clinical features (T/N stage, grade and ER status) on PBC and CBC in prognostic evaluation. Thus, clinical parameters after DR based on interval time were incorporated into the nomogram for prognostic predicting BCCM. Concordance index was 0.773 (95% CI, 0.769 to 0.776) in training cohort (n=8869), and 0.819 (95% CI, 0.813 to 0.826) in validation cohort (n=4435).Conclusions:Bilateral heterogeneous characteristics and interval time were determinant prognostic factors of MBBC. The DR nomogram may help clinical prognostic evaluation.


2021 ◽  
Vol 27 (3) ◽  
pp. 201-206
Author(s):  
Özlem Mermut ◽  
Aysun Ozsoy Ata ◽  
Didem Can Trabulus

Abstract Objective: We compared mono-isocenter and dual-isocenter plans in synchronous bilateral breast cancer (SBBC), which is defined as tumours occurring simultaneously in both breasts, and evaluated the effects of these differences in plans on organs-at-risk (OARs). Materials and methods: We evaluated 10 women with early stage, nod negative (Tis-2N0M0) SBBC. The treatment dose was determined to be 50 Gy. We used mean dose and VXGy to evaluate the OARs. To evaluate the effectiveness of treatment plans, Homogeneity index (HI), conformity index (CI) and sigma index (SI) and monitor units (MU) of monoisocenter (MIT) and dual-isocenter (DIT) plans were compared. During bilateral breast planning, for the single-centre plan, the isocenter was placed at the center of both breasts at a depth of 3-4 cm. For the two-center plan, dual-isocenters were placed on the right and left breasts. Results: No significant difference between the techniques in terms of the scope of the target volume was observed. Statistically significant results were not achieved in MIT and DIT plans for OARs. Upon comparing MIT and DIT, the right-side monitor unit (MU) value in DIT (p = 0.011) was statistically significantly lower than that in MIT. Upon comparing right-left side MIT and DIT, the MU value (p = 0.028) was significantly lower in DIT than MIT. Conclusion: SBBC irradiation is more complex than unilateral breast radiotherapy. No significant difference between both techniques and OARs was observed. However, we recommend MIT as a priority technique due to the ability to protect OARs, ease of administration during treatment, and the fact that the patient stays in the treatment unit for a shorter period of time.


Author(s):  
Smitha V. Gollamudi ◽  
Rebecca S. Gelman ◽  
Gloria Peiro ◽  
Lindsey Schneider ◽  
James L. Connolly ◽  
...  

2021 ◽  
pp. 72-73
Author(s):  
B Santhi ◽  
S Savitha ◽  
S Sujitha

Synchronous bilateral breast cancer is dened as two tumours diagnosed within 6 month interval and those above 6 months termed as metachronous breast cancer though there is difference in time interval specied by various clinicians. SBBC is a rare entity with incidence of 0.3 – 1.2% though it is recently increasing due to improved life expectancy after treatment and routine use of contralateral mammography. It is considered that synchronous breast tumours are independent tumours than to be secondary to metastatic spread from primary. Presence of indraductal component, different histology and different degree of differentiation implies that 2 they are independent tumors. Mostly women with BSBC are treated with aggressive measures as they are thought to be aggressive. Recently overall consensus is that bilateral breast cancer is amenable to breast conservation surgeries 1 without compromising surviva


2007 ◽  
Vol 33 (9) ◽  
pp. 1123-1123
Author(s):  
T IRVINE ◽  
D ALLEN ◽  
C GILLETT ◽  
I FENTIMAN ◽  
H HAMED

Sign in / Sign up

Export Citation Format

Share Document